Epidemiological and economic effects of priming with the whole-cell bordetella pertussis vaccine

JAMA Pediatrics

Volumn 170, Issue 5, 2016, Pages 459-465

  DeAngelis, Haedi ^a   Scarpino, Samuel V ^b   Fitzpatrick, Meagan C ^c   Galvani, Alison P ^c   Althouse, Benjamin M ^a,b  

^a NEW MEXICO STATE UNIVERSITY   (United States)

^b SANTA FE INSTITUTE   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

ARTICLE; BRAIN DISEASE; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HUMAN; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PERTUSSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEIZURE; SIMULATION; VACCINATION; ADOLESCENT; AGE DISTRIBUTION; BIOLOGICAL MODEL; BORDETELLA PERTUSSIS; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; INCIDENCE; MALE; PRESCHOOL CHILD; PROCEDURES; THEORETICAL MODEL; UNITED STATES; WHOOPING COUGH; YOUNG ADULT;

ADOLESCENT; AGE DISTRIBUTION; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PERTUSSIS VACCINE; UNITED STATES; VACCINATION; WHOOPING COUGH; YOUNG ADULT;

EID: 84965113397     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2016.0047     Document Type: Article

References (37)

1. Jackson DW, Rohani P. Perplexities of pertussis: Recent global epidemiological trends and their potential causes. Epidemiol Infect. 2014;142(4):672-684.
2. Centers for Disease Control and Prevention. Pertussis (whooping cough): Surveillance and reporting. http://www.cdc.gov/pertussis/surv-reporting.html. Accessed March 17, 2015.
3. Elam-Evans LD, Yankey D, Singleton JA, Kolasa M; Centers for Disease Control and Prevention (CDC). National, state, and selected local area vaccination coverage among children aged 19-35 months: United States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(34):741-748.
4. World Health Organization. Global routine vaccination coverage, 2013. Wkly Epidemiol Rec. 2014;21(47):571-578.
5. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111(2): 787-792.
6. Edwards KM. Unraveling the challenges of pertussis. Proc Natl Acad Sci U S A. 2014;111(2): 575-576.
7. Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med. 2015;13(1):146.
8. Castagnini LA, Healy CM, Rench MA, Wootton SH, Munoz FM, Baker CJ. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis. 2012;54(1): 78-84.
9. Healy CM, Rench MA,Wootton SH, Castagnini LA. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J. 2015;34(1):22-26.
10. Meade BD, Plotkin SA, Locht C. Possible options for new pertussis vaccines. J Infect Dis. 2014;209(suppl 1):S24-S27.
11. Thorstensson R, Trollfors B, Al-Tawil N, et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine, BPZE1: A single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014;9(1):e83449.
12. Locht C, Mielcarek N. Live attenuated vaccines against pertussis. Expert Rev Vaccines. 2014;13(9): 1147-1158.
13. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med. 2013;368(6):581-582.
14. WittMA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis. 2013; 56(9):1248-1254.
15. Sheridan SL,Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308(5):454-456.
16. Hethcote HW. An age-structured model for pertussis transmission. Math Biosci. 1997;145(2): 89-136.
17. Centers for Disease Control and Prevention. Vaccine information statements (VIS): Diphtheria, Tetanus, and Pertussis (DTaP) VIS. http://www.cdc .gov/vaccines/hcp/vis/vis-statements/dtap.html. Accessed February 2, 2015.
18. McGarry LJ, Krishnarajah G, Hill G, et al. Cost-effectiveness of Tdap vaccination of adults aged-65 years in the prevention of pertussis in the US: A dynamic model of disease transmission. PLoS One. 2014;9(1):e72723.
19. Howson CP, Howe CJ, Fineberg HV, eds. Adverse effects of pertussis and rubella vaccines. Washington, DC: National Academies Press; 1991.
20. Ray P, Hayward J,Michelson D, et al; Vaccine Safety Datalink Group. Encephalopathy after whole-cell pertussis or measles vaccination: Lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J. 2006;25(9): 768-773.
21. Agency for Healthcare Research and Quality. HCUP: Overview of the National (Nationwide) Inpatient Sample (NIS). http://www.hcup-us.ahrq .gov/nisoverview.jsp. Published 2012. Accessed June 2, 2014.
22. Lee GM, Lett S, Schauer S, et al; Massachusetts Pertussis Study Group. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39(11):1572-1580.
23. Lee GM, Murphy TV, Lett S, et al. Cost effectiveness of pertussis vaccination in adults. Am J PrevMed. 2007;32(3):186-193.
24. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21 (5):402-408.
25. Arias E. United states life tables, 2008. Natl Vital Stat Rep. 2012;61(3):1-63.
26. World Health Organization. Pertussis. http://www.who.int/biologicals/vaccines/pertussis/en/. Accessed May 19, 2015.
27. World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85 (40):385-400.
28. Wearing HJ, Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog. 2009;5(10):e1000647.
29. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5)(suppl):S58-S61.
30. Edwards KM, Berbers GA. Immune responses to pertussis vaccines and disease. J Infect Dis. 2014; 209(suppl 1):S10-S15.
31. Warfel JM, Edwards KM. Pertussis vaccines and the challenge of inducing durable immunity. Curr Opin Immunol. 2015;35:48-54.
32. WilliamsWW, Lu P-J, O'Halloran A, et al; Centers for Disease Control and Prevention (CDC). Noninfluenza vaccination coverage among adults: United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(5):95-102.
33. Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England andWales, 2012-2013. Clin Infect Dis. 2015;60(3):333-337.
34. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014;312(18):1897-1904.
35. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: An observational study. Lancet. 2014;384(9953):1521-1528.
36. Atkins KE, Fitzpatrick MC, Galvani AP, Townsend JP. Cost-effectiveness of pertussis vaccination during pregnancy in the US. Am J Epidemiol. In press.
37. Plotkin SA. The pertussis problem. Clin Infect Dis. 2014;58(6):830-833.